Euro-Med Laboratories Phils. (EURO)
EURO is engaged in the manufacture of pharmaceutical products such as large and small volume parenterals and other solutions. The Company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation and dialysis.
EURO is considered a defensive stock which has very little movement against a fluctuating economy. However, a defensive can perform better than a flat or down market.
Net Income rose 8.91% from previous year
58% of Outstanding Shares is owned by U.S. Automotive Co., Inc.
20% of Outstanding Shares is owned by U.S. AUTOCO
Euro-Med’s customers are hospitals, clinics, drugstores, medical distributors and traders as well as industrial/commercial accounts. The company’s customer base is composed of more than 8000 institutions nationwide.
|3Q2014||3Q2015||%Year On Year|
|Net Income After Tax||34,977,484||41,734,070||16.18961678|
|as of Sept. 30, 2015||2014||% Year On Year|
|Cash on Hand and Revolving Funds||26,491,206.00||43,366,486.00|
|Cash in Banks||832,698,826.00||798,839,439.00|
Currently the company holds the trademarks and rights to the following: Lidex, Lidemol, Synelar and Dobutrex.
The company’s market capitalization is PHP7,031,760,323.40 and pay regular cash dividends. We see EURO as an ideal long term investment with an outlook of about 12 to 18 months with an estimated 60%++ gains.
Price Movement Analysis
|Benchmark Price (Market Cap / Outstanding Shares)||1.71|
|Closing Price as of this writing||1.71|
|52 wk High||2.89|
|52 wk Low||1.06|
|SMA(20) CrossUnder EMA(13)||HOLD|
|Holding Period||12 months or shorter|